Repligen Expands US Manufacturing Facility
PTSM: Pharmaceutical Technology Sourcing and Management
A facility expansion adds space for production of Repligen’s tangential flow system.
Repligen Corp. has completed an 11,000-sq-ft expansion of its US manufacturing facility, which includes a dedicated space for the production and assembly of the company’s Alternating Tangential Flow System
The ATF System is a product line used to increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment.
The facility upgrade also expands on areas dedicated to cell culture research and development as well as manufacturing and support of the company's ELISA test kits and its OPUS line of pre-packed chromatography columns. An additional 7,500-sq-ft feet is reserved for future expansion of the Waltham facility.
Source: Repligen Corporation
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
